Evidence map›Paper›PMID 29202630›Full record

ArticleActa oncologica (Stockholm, Sweden)2018

Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database.

Deirdre Cronin-Fenton, Timothy L Lash, Thomas P Ahern, Per Damkier, Peer Christiansen, Bent Ejlertsen, Henrik T Sørensen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. The association between perioperative opioids and breast cancer recurrence: a narrative review of the literature.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2023
    Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Deirdre Cronin-Fentona Department of Clinical Epidemiology , Aarhus University , Aarhus , Denmark.
Timothy L Lasha Department of Clinical Epidemiology , Aarhus University , Aarhus , Denmark.
Thomas P Ahernc Departments of Surgery and Biochemistry, Larner College of Medicine , University of Vermont , Burlington , VT , USA.
Per Damkierd Department of Clinical Biochemistry and Pharmacology , Odense University Hospital , Odense , Denmark.
Peer Christiansenf Breast Unit, Aarhus University Hospital/Randers Regional Hospital , Aarhus , Denmark.
Bent Ejlertseng Danish Breast Cancer Cooperative Group , Copenhagen , Denmark.
Henrik T Sørensena Department of Clinical Epidemiology , Aarhus University , Aarhus , Denmark.
Aarhus University · DKDanish Breast Cancer Cooperative Group · DKStanford University · USUniversity of Southern Denmark · DKUniversity of Vermont · US

Funding

New and integrated perspectives on modification of tamoxifen effectivenessR01CA166825 · NCI · EMORY UNIVERSITY · PI LASH, TIMOTHY L. · 2013 to 2017
$2.8M
Modification of tamoxifen effectiveness by gene polymorphisms and other drugsR01CA118708 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LASH, TIMOTHY L. · 2006 to 2009
$963k
NCI NIH HHS R01 CA118708NCI NIH HHS R01 CA166825
6 · The paper itself

Abstract

backgroundMyriad reports suggest that frequently used prescription drugs alter the viability of breast cancer cells in pre-clinical studies. Routine use of these drugs, therefore, may impact breast cancer prognosis, and could have important implications for public health.

methodsThe Danish Breast Cancer Group (DBCG) clinical database provides high-quality prospectively collected data on breast cancer diagnosis, treatment, and routine follow-up for breast cancer recurrence. Individual-level linkage of DBCG data to other population-based and medical registries in Denmark, including the Danish National Prescription Registry, has facilitated large population-based pharmacoepidemiology studies. A unique advantage of using DBCG data for such studies is the ability to investigate the association of drugs with breast cancer recurrence rather than breast cancer mortality - which may be misclassified - or all-cause mortality. Here we summarize findings from pharmacoepidemiological studies, based on DBCG data, on the association between routinely used prescription drugs and risk of breast cancer recurrence.

resultsOur findings suggest that concurrent use of glucocorticoids, ACE inhibitors, aspirin, NSAIDs, selective COX-2 inhibitors, digoxin, and opioids has little impact on breast cancer recurrence. Similarly, patients who use SSRIs concurrently with tamoxifen treatment are not at increased risk of recurrence. In contrast, post-diagnostic use of simvastatin, a lipophilic statin, correlates with a decreased risk of breast cancer recurrence, providing a rationale for a prospective randomized clinical trial investigating simvastatin as an adjuvant therapy for breast cancer.

conclusionAs a whole, findings of pharmacoepidemiological studies based on DBCG data provide reassurance to physicians and healthcare personnel who provide supportive care during and after cancer (including prescriptions for comedications) and to breast cancer survivors for whom the risk of breast cancer recurrence is a major concern.

Indexed as

Disease ProgressionNeoplasm Recurrence, LocalAdrenergic beta-AntagonistsAnalgesics, OpioidAngiotensin-Converting Enzyme InhibitorsAnti-Inflammatory Agents, Non-SteroidalAspirinBreast NeoplasmsCardiotonic AgentsCyclooxygenase 2 InhibitorsDatabases, FactualDenmarkDigoxinEstrogen AntagonistsFemaleGlucocorticoidsAdrenergic beta-AntagonistsAnalgesics, OpioidAngiotensin-Converting Enzyme InhibitorsAnti-Inflammatory Agents, Non-SteroidalAspirinCardiotonic AgentsCyclooxygenase 2 InhibitorsDigoxinEstrogen AntagonistsGlucocorticoidsHydroxymethylglutaryl-CoA Reductase InhibitorsPlatelet Aggregation InhibitorsSelective Serotonin Reuptake InhibitorsSimvastatinTamoxifen

Identifiers

PMID29202630
PMCPMC13235280
OpenAlexW2774753533

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.